

Adherium receives \$1.5m Australian R&D Tax Incentive Rebate

Highlights:

- Received \$1,515,000 Australian R&D Tax Incentive for FY23
- Developing our app to include machine learning algorithms to better manage asthma and COPD patients

Melbourne, Australia – 7 March 2024: Adherium Limited (“Adherium” or “the Company”; ASX:ADR), a leader in respiratory eHealth, remote monitoring and data management solutions today announced that it has received \$1,515,000 in cash under the Australian R&D Tax Incentive for the 2023 financial year.

Dr. Paul Mastoridis, Chief Executive Officer, commented, “R&D is the backbone of Adherium, no one else in the world has our unique digital innovations. We must continue to be the leaders in this space and we want to acknowledge the support of the Australian Government for R&D and its importance in developing our business”.

In 2023, Adherium continued to directly invest in its research and development roadmap including the use of machine learning/AI functions for its next-generation Hailie® Smartinhaler® devices as the Company embarks on developing a range of software as a medical device (SaMD) capabilities.

- ENDS -

This ASX announcement was approved and authorised for release by the Board of Adherium.

Investor Enquiries

Dr. Paul Mastoridis
Adherium Limited
Chief Executive Officer
investors@adherium.com

Media Enquiries:

Haley Chartres
HACK
Director
haley@hck.digital

About Adherium (ASX:ADR)

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management.

The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease.

Learn more at www.adherium.com